Apyx Medical Corporation received approval from the South Korean Ministry of Food and Drug Safety to commercialize its Apyx One console and single‑use handpieces, allowing the company to begin shipping the devices to South Korea in the fourth quarter of 2025. The approval opens a market that was valued at $1.7 billion in 2024 and is projected to exceed $3.9 billion by 2033, positioning Apyx to capture a share of the country’s rapidly expanding cosmetic‑surgery sector.
The Apyx One console is a multi‑functional generator that integrates the company’s Helium Plasma Platform with monopolar and bipolar energy, providing surgeons with a single‑platform solution for body‑contouring procedures. The launch targets patients who have experienced loose skin after rapid weight loss from GLP‑1 drugs—a trend that has accelerated in South Korea and has already driven demand for body‑contouring solutions in the U.S. and Europe.
Management highlighted the strategic importance of the South Korean market, noting that Seoul is a global hub for medical tourism and that the country’s GLP‑1 drug market has grown rapidly over the past two years. The company expects the new sales channel to support its 2025 revenue outlook, which has been revised upward to $50.5 million to $52.5 million from the original $47.6 million to $49.0 million guidance issued earlier in the year. The guidance increase reflects stronger-than‑expected demand for the AYON Body Contouring System and the anticipated uptake of the Apyx One console in the region.
The AYON system, which received FDA clearance in May 2025, complements the Apyx One console by offering a comprehensive body‑contouring solution that can be deployed across multiple surgical settings. The synergy between the two products is expected to accelerate revenue growth in the Advanced Energy segment, which has been a key driver of Apyx’s recent performance. The company’s gross profit margin of 64.4% in Q3 2025, up from 63% in Q4 2024, underscores the pricing power and operational efficiency that support the upward guidance revision.
While the announcement did not trigger a significant market reaction, it signals Apyx’s continued confidence in expanding its global footprint and capitalizing on the growing demand for body‑contouring technologies. The company’s focus on the South Korean market, combined with the complementary AYON system, positions it to capture a meaningful share of a market that is expected to grow more than double over the next decade.
The launch also highlights Apyx’s broader strategy of leveraging its Helium Plasma Platform across multiple product lines, reinforcing its competitive advantage in the aesthetic medical device space and providing a foundation for future growth in other international markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.